Fabry's disease overview: Difference between revisions

Jump to navigation Jump to search
Line 5: Line 5:
==Overview==
==Overview==


* '''Fabry's disease''' (also known as '''alpha-galactosidase A deficiency, ceramide trihexosidase deficiency, angiokeratoma corporis diffusum)''' is an [[X-linked recessive]] inherited [[lysosomal storage disease|lysosomal storage disorder.]]  
** '''Fabry disease''' (also known as '''alpha-galactosidase A deficiency, ceramide trihexosidase deficiency, angiokeratoma corporis diffusum, Anderson Fabry disease)''' is an [[X-linked recessive]] inherited [[Lysosomal storage disease|lysosomal storage disorder.]]
* It occurs as a result of the body's inability to make an enzyme alpha-galactosidase A. This enzyme in-turn is responsible for breaking down a type of fat called [[Globotriaosylceramide 3-beta-N-acetylgalactosaminyltransferase|globotriaosylceramide]] (Gb3 or GL-3) into building blocks that are used by the cells of the body.  
** X linked inherited disorders are transmitted
* The abnormal accumulation of this fat is identified as the cause behind the varied manifestations associated with the disease
** It occurs as a result of the body's inability to make the enzyme alpha-galactosidase A. This enzyme encoded by the GLA gene located on the long arm of the X chromosome (q21-22) is in-turn responsible for breaking down a type of fat called [[Globotriaosylceramide 3-beta-N-acetylgalactosaminyltransferase|globotriaosylceramide]] (Gb3 or GL-3) into building blocks that are used by the cells of the body.
* The three main organ systems typically involved included the heart, kidney and central nervous system
** The Glycosphingolipid storage initiates a cascade of events that begins with the dysfunction of basic metabolic processes on the cellular level followed by progression to cell death, inflammatory events, and progressive major organ dysfunction.[2]
** Three main organ systems commonly affected include the brain, heart and kidney.
** Prenatal and neonatal studies of the histopathology of Fabry disease have confirmed that pathogenic GL3 accumulations occur in the maternal region of the placenta, fetal tissues, and the fetal placenta regions of affected males. In male fetuses affected these accumulations have been found in renal, myenteric plexus, and liver cells.This prenatal storage suggests that the process of Fabry disease may lead to early childhood symptoms[3][4]
** Fabry disease is a rare condition that can affect people regardless of their ethnic background. The prevalence for Fabry's disease is estimated to range from 0.27 to 1.69 per 100,000 in men, and 0.33 to 3.47 per 100,000 in women.
** The disorder is termed X linked as the mutated gene is located only on the X chromosome. In males (who have only one X chromosome), one altered copy of the ''GLA'' gene is sufficient to cause the condition however since females have two copies of the X chromosome, one altered copy of the gene in the cells usually leads to less severe symptoms in females than in males and in some cases none at all.
** The significance of Fabry's disease stems from data that suggests significant medical problems in many females who have only one altered copy of the ''GLA'' gene unlike other X linked diseases that generally have most women carriers remaining asymptomatic. The women carrying this mutation only on one X chromosome can experience many of the classic features of the disorder, including nervous system abnormalities, kidney failure and heart disease. Other possible symptoms reported include high blood pressure, chronic pain and fatigue.
** A small percentage of females who carry a mutation in one copy of the ''GLA'' gene never develop signs and symptoms of Fabry disease.[5]
*  
*  


==References==
==References==
{{Reflist|2}}
<br />{{Reflist|2}}

Revision as of 21:26, 16 August 2020

Fabry's disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Fabry's disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Fabry's disease overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Fabry's disease overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Fabry's disease overview

CDC on Fabry's disease overview

Fabry's disease overview in the news

Blogs on Fabry's disease overview

Directions to Hospitals Treating Fabry's disease

Risk calculators and risk factors for Fabry's disease overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

    • Fabry disease (also known as alpha-galactosidase A deficiency, ceramide trihexosidase deficiency, angiokeratoma corporis diffusum, Anderson Fabry disease) is an X-linked recessive inherited lysosomal storage disorder.
    • X linked inherited disorders are transmitted
    • It occurs as a result of the body's inability to make the enzyme alpha-galactosidase A. This enzyme encoded by the GLA gene located on the long arm of the X chromosome (q21-22) is in-turn responsible for breaking down a type of fat called globotriaosylceramide (Gb3 or GL-3) into building blocks that are used by the cells of the body.
    • The Glycosphingolipid storage initiates a cascade of events that begins with the dysfunction of basic metabolic processes on the cellular level followed by progression to cell death, inflammatory events, and progressive major organ dysfunction.[2]
    • Three main organ systems commonly affected include the brain, heart and kidney.
    • Prenatal and neonatal studies of the histopathology of Fabry disease have confirmed that pathogenic GL3 accumulations occur in the maternal region of the placenta, fetal tissues, and the fetal placenta regions of affected males. In male fetuses affected these accumulations have been found in renal, myenteric plexus, and liver cells.This prenatal storage suggests that the process of Fabry disease may lead to early childhood symptoms[3][4]
    • Fabry disease is a rare condition that can affect people regardless of their ethnic background. The prevalence for Fabry's disease is estimated to range from 0.27 to 1.69 per 100,000 in men, and 0.33 to 3.47 per 100,000 in women.
    • The disorder is termed X linked as the mutated gene is located only on the X chromosome. In males (who have only one X chromosome), one altered copy of the GLA gene is sufficient to cause the condition however since females have two copies of the X chromosome, one altered copy of the gene in the cells usually leads to less severe symptoms in females than in males and in some cases none at all.
    • The significance of Fabry's disease stems from data that suggests significant medical problems in many females who have only one altered copy of the GLA gene unlike other X linked diseases that generally have most women carriers remaining asymptomatic. The women carrying this mutation only on one X chromosome can experience many of the classic features of the disorder, including nervous system abnormalities, kidney failure and heart disease. Other possible symptoms reported include high blood pressure, chronic pain and fatigue.
    • A small percentage of females who carry a mutation in one copy of the GLA gene never develop signs and symptoms of Fabry disease.[5]

References